{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:49:35Z","timestamp":1791460175951,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011033","name":"Thermo Fisher Scientific","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011033","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Dizal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"DOI":"10.1007\/s40291-026-00884-z","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T10:53:44Z","timestamp":1791456824000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analytical and Clinical Validation of the Oncomine Dx Express Test, an In Vitro Diagnostic-Labeled Assay, for Genomic Profiling of FFPE Tumor Samples"],"prefix":"10.1007","author":[{"given":"Angie","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumitha","family":"Nallu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luming","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Bigley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Bridi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Ostrowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thilanka","family":"Jayaweera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu","family":"Jasti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Fehon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader","family":"Ezzedine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diarra","family":"Hassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swasti","family":"Raut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Breitenfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Dykman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasha","family":"Delacour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hradecky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hatch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Wunsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gokhan","family":"Yavas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Del","family":"Rodrigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeoffrey","family":"Schageman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Kuzmenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vrunda","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Ji","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsueh Ping","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gripkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9282-0708","authenticated-orcid":false,"given":"Cec\u00edlia","family":"Dur\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Marie Velasco","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"issue":"7","key":"884_CR1","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","volume":"35","author":"MF Mosele","year":"2024","unstructured":"Mosele MF, Westphalen CB, Stenzinger A, Barlesi F, Bayle A, Bieche I, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2024;35(7):588\u2013606.","journal-title":"Ann Oncol"},{"key":"884_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00356","volume":"3","author":"NA Pennell","year":"2019","unstructured":"Pennell NA, Mutebi A, Zhou ZY, Ricculli ML, Tang W, Wang H, et al. Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non-small-cell lung cancer using a decision analytic model. JCO Precis Oncol. 2019;3:1\u20139.","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"884_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00572-w","volume":"6","author":"L Zhong","year":"2021","unstructured":"Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther. 2021;6(1):201.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"884_CR4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","volume":"22","author":"GJ Riely","year":"2024","unstructured":"Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR, et al. Non-small cell lung cancer, Version 4.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22(4):249\u201374.","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"884_CR5","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","volume":"29","author":"J Mateo","year":"2018","unstructured":"Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO scale for clinical actionability of molecular targets (ESCAT). Ann Oncol. 2018;29(9):1895\u2013902.","journal-title":"Ann Oncol"},{"issue":"7","key":"884_CR6","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1916623","volume":"383","author":"N Howlader","year":"2020","unstructured":"Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, et al. The effect of advances in lung-cancer treatment on population mortality. N Engl J Med. 2020;383(7):640\u20139.","journal-title":"N Engl J Med"},{"issue":"8","key":"884_CR7","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","volume":"27","author":"M Wang","year":"2021","unstructured":"Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27(8):1345\u201356.","journal-title":"Nat Med"},{"issue":"12","key":"884_CR8","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1016\/j.jtho.2020.08.005","volume":"15","author":"R Caso","year":"2020","unstructured":"Caso R, Sanchez-Vega F, Tan KS, Mastrogiacomo B, Zhou J, Jones GD, et al. The underlying tumor genomics of predominant histologic subtypes in lung adenocarcinoma. J Thorac Oncol. 2020;15(12):1844\u201356.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"884_CR9","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1097\/JTO.0b013e3181ca12c4","volume":"5","author":"CL Coghlin","year":"2010","unstructured":"Coghlin CL, Smith LJ, Bakar S, Stewart KN, Devereux GS, Nicolson MC, et al. Quantitative analysis of tumor in bronchial biopsy specimens. J Thorac Oncol. 2010;5(4):448\u201352.","journal-title":"J Thorac Oncol"},{"issue":"10","key":"884_CR10","doi-asserted-by":"publisher","first-page":"3926","DOI":"10.1111\/cas.14608","volume":"111","author":"H Hayashi","year":"2020","unstructured":"Hayashi H, Tanishima S, Fujii K, Mori R, Okada C, Yanagita E, et al. Clinical impact of a cancer genomic profiling test using an in-house comprehensive targeted sequencing system. Cancer Sci. 2020;111(10):3926\u201337.","journal-title":"Cancer Sci"},{"issue":"2","key":"884_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","volume":"20","author":"E Heitzer","year":"2019","unstructured":"Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet. 2019;20(2):71\u201388.","journal-title":"Nat Rev Genet"},{"issue":"7","key":"884_CR12","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1111\/cas.13265","volume":"108","author":"T Kou","year":"2017","unstructured":"Kou T, Kanai M, Yamamoto Y, Kamada M, Nakatsui M, Sakuma T, et al. Clinical sequencing using a next-generation sequencing-based multiplex gene assay in patients with advanced solid tumors. Cancer Sci. 2017;108(7):1440\u20136.","journal-title":"Cancer Sci"},{"issue":"2","key":"884_CR13","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/cam4.4459","volume":"11","author":"KF Mileham","year":"2022","unstructured":"Mileham KF, Schenkel C, Bruinooge SS, Freeman-Daily J, Basu Roy U, Moore A, et al. Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: results of a survey of U.S. oncologists. Cancer Med. 2022;11(2):530\u20138.","journal-title":"Cancer Med"},{"key":"884_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare11030431","author":"D Horgan","year":"2023","unstructured":"Horgan D, Hamdi Y, Lal JA, Nyawira T, Meyer S, Kondji D, et al. Framework for adoption of next-generation sequencing (NGS) globally in the oncology area. Healthcare (Basel). 2023. https:\/\/doi.org\/10.3390\/healthcare11030431.","journal-title":"Healthcare (Basel)"},{"key":"884_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092258","author":"M Ili\u00e9","year":"2022","unstructured":"Ili\u00e9 M, Hofman V, Bontoux C, Heeke S, Lespinet-Fabre V, Bordone O, et al. Setting up an ultra-fast next-generation sequencing approach as reflex testing at diagnosis of non-squamous non-small cell lung cancer; experience of a single center (LPCE, Nice, France). Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14092258.","journal-title":"Cancers (Basel)"},{"key":"884_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241813788","author":"N Normanno","year":"2023","unstructured":"Normanno N, Machado JC, Pescarmona E, Buglioni S, Navarro L, Esposito Abate R, et al. European real-world assessment of the clinical validity of a CE-IVD panel for ultra-fast next-generation sequencing in solid tumors. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241813788.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"884_CR17","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jmoldx.2025.10.005","volume":"27","author":"S Stone","year":"2025","unstructured":"Stone S, Fronkier B, Zsibor\u00e1s R, Luk\u00e1cs L, Urb\u00e1n P. Results of a time and motion study of two next-generation sequencing workflows in a routine oncology biomarker profiling setting. J Mol Diagn. 2025;27(11):S1\u2013206.","journal-title":"J Mol Diagn"},{"key":"884_CR18","unstructured":"Thermo Fisher Scientific. Oncomine Dx Express test part I: test description and performance characteristics user guide. MAN0024908; 2025."},{"key":"884_CR19","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-00788","author":"JC Yang","year":"2025","unstructured":"Yang JC, Wang M, Doucet L, Fan Y, Lv D, Sun M, et al. Phase II dose-randomized study of sunvozertinib in platinum-pretreated non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations (WU-KONG1B). J Clin Oncol. 2025. https:\/\/doi.org\/10.1200\/jco-25-00788.","journal-title":"J Clin Oncol"},{"issue":"2","key":"884_CR20","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/1878-0261.13327","volume":"17","author":"S Viteri","year":"2023","unstructured":"Viteri S, Minchom A, Bazhenova L, Ou SI, Bauml JM, Shell SA, et al. Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real-world genomic datasets. Mol Oncol. 2023;17(2):230\u20137.","journal-title":"Mol Oncol"},{"key":"884_CR21","unstructured":"U.S. Food and Drug Administration. Premarket Approval (PMA): Oncomine Dx Express Test, P240040. FDA Premarket Approval (PMA) Database [13 May 2026]. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpma\/pma.cfm?id=P240040."},{"key":"884_CR22","unstructured":"U.S. Food and Drug Administration. CDRH\u2019s approach to tumor profiling next generation sequencing tests. FDA Fact Sheet [13 May 2026]. Available from: https:\/\/www.fda.gov\/media\/109050\/download."},{"key":"884_CR23","unstructured":"Thermo Fisher Scientific. Oncomine Dx Express test part II: sample purification, sequencing, and results reports user guide. MAN0024909; 2025."},{"key":"884_CR24","unstructured":"Thermo Fisher Scientific. Oncomine Dx Express test part III: Genexus\u2122 Dx Software 6.8 reference user guide. MAN0024910; 2025."},{"issue":"3","key":"884_CR25","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1080\/19466315.2016.1202859","volume":"8","author":"M Li","year":"2016","unstructured":"Li M. Statistical methods for clinical validation of follow-on companion diagnostic devices via an external concordance study. Stat Biopharm Res. 2016;8(3):355\u201363.","journal-title":"Stat Biopharm Res"},{"issue":"10","key":"884_CR26","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/j.jtho.2018.06.019","volume":"13","author":"JW Riess","year":"2018","unstructured":"Riess JW, Gandara DR, Frampton GM, Madison R, Peled N, Bufill JA, et al. Diverse EGFR exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC. J Thorac Oncol. 2018;13(10):1560\u20138.","journal-title":"J Thorac Oncol"},{"issue":"10","key":"884_CR27","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.annonc.2023.06.011","volume":"34","author":"A Bayle","year":"2023","unstructured":"Bayle A, Bonastre J, Chaltiel D, Latino N, Rouleau E, Peters S, et al. ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe. Ann Oncol. 2023;34(10):934\u201345.","journal-title":"Ann Oncol"},{"key":"884_CR28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejca.2022.09.005","volume":"176","author":"N Normanno","year":"2022","unstructured":"Normanno N, Apostolidis K, Wolf A, Al Dieri R, Deans Z, Fairley J, et al. Access and quality of biomarker testing for precision oncology in Europe. Eur J Cancer. 2022;176:70\u20137.","journal-title":"Eur J Cancer"},{"issue":"7","key":"884_CR29","doi-asserted-by":"publisher","first-page":"e2519963","DOI":"10.1001\/jamanetworkopen.2025.19963","volume":"8","author":"S DaCosta Byfield","year":"2025","unstructured":"DaCosta Byfield S, Bapat B, Becker L, Reyes C, Chatzitheofilou I, Schroeder BE, et al. Biomarker testing approaches, treatment selection, and cost of care among adults with advanced cancer. JAMA Netw Open. 2025;8(7):e2519963.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"884_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1200\/OP.22.00611","volume":"20","author":"JA Scott","year":"2024","unstructured":"Scott JA, Lennerz J, Johnson ML, Gordan LN, Dumanois RH, Quagliata L, et al. Compromised outcomes in stage IV non-small-cell lung cancer with actionable mutations initially treated without tyrosine kinase inhibitors: a retrospective analysis of real-world data. JCO Oncol Pract. 2024;20(1):145\u201353.","journal-title":"JCO Oncol Pract"},{"key":"884_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcp.2026.102071","volume":"88","author":"A Weaver","year":"2026","unstructured":"Weaver A, Diercks A, Corral A, Sowada M, Cotten S, Stephen A, et al. First experiences in a US clinical laboratory with Oncomine Dx Express test: evaluation in formalin-fixed paraffin-embedded tissues. Mol Cell Probes. 2026;88:102071.","journal-title":"Mol Cell Probes"},{"issue":"3","key":"884_CR32","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jmoldx.2017.01.011","volume":"19","author":"LJ Jennings","year":"2017","unstructured":"Jennings LJ, Arcila ME, Corless C, Kamel-Reid S, Lubin IM, Pfeifer J, et al. Guidelines for validation of next-generation sequencing-based oncology panels: a joint consensus recommendation of the association for molecular pathology and college of American pathologists. J Mol Diagn. 2017;19(3):341\u201365.","journal-title":"J Mol Diagn"},{"issue":"3","key":"884_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264138","volume":"17","author":"CA Milbury","year":"2022","unstructured":"Milbury CA, Creeden J, Yip WK, Smith DL, Pattani V, Maxwell K, et al. Clinical and analytical validation of FoundationOne(R)CDx, a comprehensive genomic profiling assay for solid tumors. PLoS ONE. 2022;17(3):e0264138.","journal-title":"PLoS ONE"},{"key":"884_CR34","unstructured":"Illumina, Inc. TruSight Oncology Comprehensive (US) Package Insert.: Document # 200061832 v03; 2026."},{"issue":"9","key":"884_CR35","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/j.molonc.2015.05.004","volume":"9","author":"H Al-Kateb","year":"2015","unstructured":"Al-Kateb H, Nguyen TT, Steger-May K, Pfeifer JD. Identification of major factors associated with failed clinical molecular oncology testing performed by next generation sequencing (NGS). Mol Oncol. 2015;9(9):1737\u201343.","journal-title":"Mol Oncol"},{"key":"884_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17091579","author":"G Arreaza","year":"2016","unstructured":"Arreaza G, Qiu P, Pang L, Albright A, Hong LZ, Marton MJ, et al. Pre-analytical considerations for successful next-generation sequencing (NGS): challenges and opportunities for formalin-fixed and paraffin-embedded tumor tissue (FFPE) samples. Int J Mol Sci. 2016. https:\/\/doi.org\/10.3390\/ijms17091579.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"884_CR37","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.3390\/curroncol31030115","volume":"31","author":"KE Fleming","year":"2024","unstructured":"Fleming KE, Hupel A, Mithoowani H, Lulic-Kuryllo T, Valdes M. Biomarker turnaround times and impact on treatment decisions in patients with advanced non-small cell lung carcinoma at a large Canadian community hospital with an affiliated regional cancer centre. Curr Oncol. 2024;31(3):1515\u201328.","journal-title":"Curr Oncol"},{"key":"884_CR38","doi-asserted-by":"crossref","unstructured":"Gaal OI, Ungureanu A, Pop B, Tomescu A, Catana A, Man M, et al. The genomic landscape of Romanian non-small cell lung cancer patients: the insights from routine NGS testing with the Oncomine\u2122 Dx Express Test at the PATHOS Molecular Pathology Laboratory. Cancers (Basel). 2025;17(12):1947.","DOI":"10.3390\/cancers17121947"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-026-00884-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-026-00884-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-026-00884-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T10:53:46Z","timestamp":1791456826000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-026-00884-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":38,"alternative-id":["884"],"URL":"https:\/\/doi.org\/10.1007\/s40291-026-00884-z","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"assertion":[{"value":"25 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was supported by Dizal Pharmaceutical and internal funding from Thermo Fisher Scientific.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors are employees of Thermo Fisher Scientific.","order":2,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No additional datasets generated and\/or analyzed during this study are available beyond the manuscript, supplementary materials, and publicly available materials. This article summarizes the principal FDA-reviewed validation data; additional supporting information is publicly available through the FDA Premarket Approval (PMA) database for P240040 (\n                      \n                      ).","order":3,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective validation study was based on preexisting biological materials and data, which were reanalyzed using new methods. The study protocol was reviewed and approved by an accredited institutional review board (Advarra IRB, Columbia, MD, USA) before any testing activities began. All patients provided informed consent for the use of their biopsy specimens in this validation study. The informed consent forms were collected and are retained by the pharmaceutical partner or commercial vendors.","order":4,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During revision of the manuscript following peer review, InstaText was used for language editing, and an internal company AI tool was used to assist with organizing reviewer comments and improving the clarity and language of author-drafted responses. All suggested changes were reviewed by the authors, who remain fully responsible for the content.","order":7,"name":"Ethics","label":"Artificial Intelligence (AI) Use","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AC, SN, LH, TJ, MJ, DG, TB, JS, and AMVR: conceptualization, including development of the research idea, objectives, and hypothesis. AC, SN, LH, TJ, MJ, DG, TB, JS, EK, JW, and AMVR: methodology, including design of the study methods or experimental approach. AC, SN, LH, AB, ABr, EO, TJ, MJ, DG, MF, TB, NE, DH, SR, EB, AD, TD, BH, AH, SW, GY, JS, EK, JW, VS, EJK, HPC, JWi, and HG: investigation, including experiments, clinical work, fieldwork, and data collection. AC, SN, LH, TJ, MJ, DG, TB, AH, SW, GY, DR, JS, EK, JW, VS, EJK, HPC, JWi, and HG: formal analysis, including statistical, computational, and qualitative analysis. DR, HPC, JWi, HG, and CD: visualization, including creation of figures, tables, and data displays. CD: writing the original draft. AC, SN, JLC, and CD: writing, critical review, and editing. All authors have read and approved the final version.","order":8,"name":"Ethics","label":"Authors Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}